Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging;Alzheimer Disease, ...
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vizamyl’s benefits are greater than its risks and recommended that it be approved for use in the EU. The Committee noted that PET scans with Vizamyl have a high sensitivity and …